Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2022 - 05 - 03 save search
Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
Published: 2022-05-03 (Crawled : 12:20) - prnewswire.com
ORMP | $2.43 0.41% 15K
|
Health Technology
|
| O: 6.4%
H: 4.69%
C: 0.88%
insulin enroll phase 3
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
BTAI 4 | $2.71 -1.46% 34K
|
Health Technology
|
| O: 4.1%
H: 1.65%
C: 1.01%
treatment disease trial therapeutics alzheimer’s phase 3 alzheimer's
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
BHC | $8.525 -1.22% 190K
|
Health Technology
|
| O: 0.43%
H: 1.3%
C: -0.74%
nov03 treatment research trial phase 3
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
RVPH | $3.35 -3.74% 19K
|
|
| O: -8.29%
H: 14.69%
C: 10.17%
treatment brilaroxazine schizophrenia phase 3
Gainers vs Losers
| 43% | 57% |
Top 10 Gainers
TPET | $0.4801 107.75% 16M
|
n/a
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $7.41 78.13% 14M
|
Manufacturing
SPCB | $0.4278 55.0% 17M
|
Electronic Technology
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 25M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
JAGX | $0.1668 40.4% 110M
|
Health Technology
MCBC | $13.84 39.38% 450K
|
Finance
SNGX | $0.5155 33.52% 3.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.